Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Genomic Markers of Immune Infiltration in Actinic Keratosis Treated with Imiquimod
NCT03914417Phase 2Completed
- Sponsor
- Icahn School of Medicine at Mount Sinai
- Start
- Jan 2013
- Primary completion
- Apr 2015
- Modality
- Nucleic Acid-Directed Small Molecules, Irreversible Covalent Inhibitors, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of imiquimod in actinic keratosis (AK), sponsored by Icahn School of Medicine at Mount Sinai. Primary endpoint: Number of Responders at Day 70. Started Jan 2013; status: completed.
02
Drugs
imiquimod
03
Conditions
actinic keratosis (AK)
Beyond the preview
Go deeper on NCT03914417.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03914417.